Arformoterol
Verifiedfieldschanged
Verifiedrevid457140599
Width250
UsanArformoterol tartrate
TradenameBrovana
Medlineplusa602023
DailymedidArformoterol
Routes of administrationInhalation
Atc prefixNone
Legal usRx-only
Legal us comment[1]
Protein bound52–65%
Elimination half-life26 hours
Cas number67346-49-0
Pubchem3083544
Iuphar ligand7479
DrugbankDB01274
Chemspiderid2340731
UniiF91H02EBWT
KeggD07463
Kegg 2D02981
Chebi408174
Chembl1201137
Iupac nameN-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
C19
H24
N2
O4
Stdinchi1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
StdinchikeyBPZSYCZIITTYBL-YJYMSZOUSA-N

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]

It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as a generic medication.[3]

Medical uses

Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]

References

  1. ^ "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
  2. ^ Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810
  3. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.